Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 301–400 of 1,001
Alogliptin: a new addition to the class of DPP-4 inhibitors
Rendell, M. (2009) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s4312 · Cited by 64
Davies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
“Importantly, patients with type 2 diabetes have an impaired incretin function, most probably because of a decrease in GLP-1 response to food and pancreatic resistance to GIP, which makes the option of incretin-based therapy attractive in this common chronic condition [17,18].”
BackgroundEmerging Concepts in the Pathophysiology of Type 2 Diabetes Mellitus
Surampudi, P. N., John‐Kalarickal, J., & Fonseca, V. A. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20113 · Cited by 95
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 73
Sonne, D. P., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0309 · Cited by 65
Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Zinman, B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.003 · Cited by 70
Ranganath, L. R. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.043232 · Cited by 66
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Florentin, M., Kostapanos, M. S., & Papazafiropoulou, A. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i2.85 · Cited by 75
Svendsen, P. F., Nilas, L., Madsbad, S., & Holst, J. J. (2009) · Metabolism · doi:10.1016/j.metabol.2008.11.009 · Cited by 69
“Several conditions involving insulin resistance and glucose intolerance have been associated with altered incretin effect [5-9].”
BackgroundWhitaker, G. M., Lynn, F. C., McIntosh, C. H. S., & Accili, E. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032675 · Cited by 64
“There is a reduced incretin effect in human T2DM patients [43], which has been attributed to reduced ß-cell responsiveness to GIP [44] and, to a lesser extent, GLP-1 [45].”
Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 65
Nishizawa, M., Nakabayashi, H., Uehara, K., Nakagawa, A., Uchida, K., & Koya, D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00565.2012 · Cited by 63
“The central role of the enteroinsular axis in meal-induced insulin secretion has attracted notice since it was known that at least more than 50% of the insulin released upon glucose ingestion was derived from gastrointestinal factors (34, 44).”
BackgroundFate of the beta-cell in the pathophysiology of type 2 diabetes
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09076 · Cited by 69
Matikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H. (2014) · Diabetes Care · doi:10.2337/dc13-1283 · Cited by 63
“A severely reduced incretin response is a uniform finding in type 2 diabetes, in which the β-cell insulin secretion due to incretins may be reduced to < 20% from that of healthy subjects (2).”
BackgroundResultAlpha-cell paracrine signaling in the regulation of beta-cell insulin secretion
Holter, M. M., Saikia, M., & Cummings, B. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934775 · Cited by 63
“Certainly, human patients with T2DM display a blunted incretin effect of GLP-1, and defects in meal-induced intestinal GLP-1 secretion (91), suggesting that the paracrine action of alpha-cell-derived GLP1 may be necessary to combat this diminished peripheral incretin action of gut-derived GLP-1.”
BackgroundExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
“Patients with Type 2 diabetes have been demonstrated to exhibit a loss of the incretin effect [7].”
BackgroundHe, Y., Sabo, R., Campestrini, J., Wang, Y., Ligueros‐Saylan, M., Lasseter, K. C., Dilzer, S. C., Howard, D., & Dole, W. P. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0312-6 · Cited by 66
“Patients with type 2 diabetes mellitus show impaired GLP-1 secretion, which may explain, at least in part, the reduced incretin effect seen in these patients [17, 22].”
Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63
“An impaired incretin effect in patients with T2DM may contribute to disease pathology [24,25,41,42].”
BackgroundLiraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., & Campbell, R. K. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m134 · Cited by 63
Vardarli, I., Nauck, M. A., Köthe, L. D., Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2178 · Cited by 61
“without the nutrient-stimulated release of incretin hormones, and it could be speculated that this may lead to an at least partial restoration of the reduced incretin effect (9).”
BackgroundMethodResultSelf-citationRole of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 63
“3,16 The signifi cant reduction in the incretin effect seen in patients with T2DM has been attributed to several factors, including impaired secretion of GLP-1, accelerated metabolism of GLP-1 and GIP, and defective responsiveness to both hormones.”
BackgroundInfluentialBastin, M., & Andreelli, F. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s191438 · Cited by 62
An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus
Mahgoub, M., Ali, I. I., Adeghate, J. O., Tekes, K., Kalász, H., & Adeghate, E. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119328 · Cited by 74
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.012 · Cited by 74
Self-citationG protein-coupled receptors as new therapeutic targets for type 2 diabetes
Reimann, F., & Gribble, F. M. (2015) · Diabetologia · doi:10.1007/s00125-015-3825-z · Cited by 70
“iological incretin effect, responsible for about 50% of postprandial insulin secretion [12].”
BackgroundChondronikola, M., Harris, L. L. S., & Klein, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12527 · Cited by 61
A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling
Ehses, J. A., Lee, S. S. T., Pederson, R. A., & McIntosh, C. H. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103023200 · Cited by 61
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 69
Exenatide: From the Gila Monster to the Pharmacy
Triplitt, C. L., & Chiquette, E. (2006) · Journal of the American Pharmacists Association · doi:10.1331/154434506775268698 · Cited by 69
Buchwald, H., Dorman, R. B., Rasmus, N. F., Michalek, V. N., Landvik, N. M., & Ikramuddin, S. (2014) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.01.032 · Cited by 59
“It has been shown that GLP-1 secretion is reduced in patients with type 2 diabetes [28,29], which may be responsible for the hyperglycemia of this disease [30].”
BackgroundWang, A., Dorso, C. R., Kopcho, L. M., Locke, G. A., Langish, R. A., Harstad, E. B., Shipkova, P. A., Marcinkeviciene, J. A., Hamann, L. G., & Kirby, M. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-2 · Cited by 59
“Incretins account for up to 60% of the post-prandial insulin secretion in healthy individuals, but the incretin response is impaired in T2DM [3].”
BackgroundInfluentialDipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 63
“There is a reduced incretin response in many type 2 diabetic patients (41, 42) that is largely due to a reduction in circulating levels of GLP-1 (43,”
BackgroundMeier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Self-citationMechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
Patriti, A., Facchiano, E., & Donini, A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000134632.08789.df · Cited by 58
The entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 72
Wu, T., Bound, M. J., Zhao, B. R., Standfield, S. D., Bellon, M., Jones, K. L., Horowitz, M., & Rayner, C. K. (2013) · Diabetes Care · doi:10.2337/dc12-2294 · Cited by 58
“In type 2 diabetes, the incretin effect is impaired (7), related at least partly to a diminished insulinotropic effect of GIP, while that of GLP-1 is preserved (8).”
BackgroundAlssema, M., Rijkelijkhuizen, J. M., Holst, J. J., Teerlink, T., Scheffer, P. G., Eekhoff, E. M. W., Gastaldelli, A., Mari, A., Hart, L. M., Nijpels, G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0487 · Cited by 56
Zheng, M.-Y., Yang, J.-H., Shan, C.-Y., Zhou, H.-T., Xu, Y.-G., Wang, Y., Ren, H.-Z., Chang, B.-C., & Chen, L.-M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-73 · Cited by 59
“As previously reported, the functional integrity of GLP-1-secreting cells is seriously impaired even in the context of mild diabetes, and GLP-1 is deficient in patients with T2D [19,20].”
BackgroundDipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes
Augustyns, K., der Veken, P. V., Senten, K., & Haemers, A. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.4.499 · Cited by 59
Zhang, X., Wang, Z., Huang, Y., & Wang, J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01354.x · Cited by 57
“In T2DM patients, the incretin effects were found to be impaired [18].”
BackgroundHarris, K. B., & McCarty, D. J. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 57
“In 746 patients with T2DM, monotherapy with liraglutide 1.2 and 1.8 mg daily compared with glimepiride 8 mg daily significantly decreased HbA1c (–0.84% and −1.14% versus –0.51”
BackgroundInfluentialBarnett, A., Allsworth, J., Jameson, K., & Mann, R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199691 · Cited by 57
Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Translational approaches: from fatty liver to non-alcoholic steatohepatitis.
Rosso, N., Chávez-Tapia, N. C., Tiribelli, C., & Bellentani, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9038 · Cited by 65
Tessari, P., Kiwanuka, E., Cristini, M., Zaramella, M., Enslen, M., Zurlo, C., & Garcia‐Rodenas, C. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.698 · Cited by 55
“In type 2 diabetes, GIP secretion and action may be impaired, normal, or increased [22,24,25].”
BackgroundHerzberg‐Schäfer, S., Heni, M., Stefan, N., Häring, H. ‐., & Fritsche, A. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 57
“The incretin effect is reduced in patients with type 2 diabetes from 70% (see above) to 30% [3], which is a significant reduction compared to healthy individuals.”
BackgroundUgale, S. M., Gupta, N., Modi, K. D., Kota, S. K., Satwalekar, V., Naik, V., Swapna, M., & Kumar, K. H. (2014) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-014-0089-y · Cited by 59
“The GLP-1 response is defective in T2DM leading to diminished first phase of insulin secretion [36].”
BackgroundMulvihill, E. E. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.023 · Cited by 62
“In healthy individuals GIP and GLP-1 account for 50–70% of the postprandial rise in insulin and in patients with T2DM, the incretin effect is impaired and only accounts for approximately 20% of the postprandial rise in insulin [17,18].”
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
“Several studies have indicated that the incretin effect in patients with type 2 diabetes is impaired or absent [23].”
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Bariatric surgery and obesity: influence on the incretins
Laferrère, B. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.8 · Cited by 58
GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_3 · Cited by 62
“This effect describes the phenomenon that orally ingested glucose leads to a much larger insulin response than an isoglycemic intravenous glucose load (Creutzfeldt 1979; Nauck et al. 1986 ).”
BackgroundInhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes
Kimple, M. E., Neuman, J. C., Linnemann, A. K., & Casey, P. J. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.40 · Cited by 55
Marathe, C. S., Rayner, C. K., Bound, M., Checklin, H., Standfield, S., Wishart, J., Lange, K., Jones, K. L., & Horowitz, M. (2014) · Diabetes · doi:10.2337/db13-1757 · Cited by 53
“Incretin Effect and GIGD The incretin effect (percentage) was calculated from incremental area under the curve (iAUC) for plasma C-peptide as [(iAUCID(0–120) 2 iAUCIV(0–120)) / iAUCID(0–120)]3 100 (5).”
BackgroundMethodInfluentialKang, Z. F., Deng, Y., Zhou, Y., Fan, R. R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2013) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 54
“Impaired incretin effects are found in type 2 diabetes [3, 4].”
BackgroundJavorský, M., Gotthardová, I., Klimčáková, L., Kvapil, M., Židzik, J., Schroner, Z., Doubravová, P., Gaľa, I., Dravecká, I., & Tkáč, I. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12682 · Cited by 63
Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide
Yamada, Y., Miyawaki, K., Tsukiyama, K., Harada, N., Yamada, C., & Seino, Y. (2006) · Diabetes · doi:10.2337/db06-s011 · Cited by 56
“gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide”
BackgroundMethodInfluentialPotential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., et al. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/6820377 · Cited by 50
“Further, study showed that patients with type 2 diabetes (T2D) had an impaired incretin effect after glucose load [3].”
BackgroundIrwin, N., Gault, V., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513381 · Cited by 53
“A defect in the endogenous incretin system is thought to play a significant part in the pathogenesis of type 2 diabetes [3].”
BackgroundNeumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 59
Kodra, J. T., Jørgensen, A. S., Andersen, B., Behrens, C., Brand, C. L., Christensen, I. T., Guldbrandt, M., Jeppesen, C. B., Knudsen, L. B., Madsen, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015599 · Cited by 52
The Duodenum harbors a Broad Untapped Therapeutic Potential
van Baar, A. C. G., Nieuwdorp, M., Holleman, F., Soeters, M. R., Groen, A. K., & Bergman, J. J. G. H. M. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.02.010 · Cited by 51
Zhang, X., Young, R. L., Bound, M., Hu, S., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2019) · Diabetes Care · doi:10.2337/dc18-2156 · Cited by 52
“), glucose administrationdknown as the incretin effectdand play a major role in gastrointestinal-mediated glucose disposal (GIGD) (1).”
BackgroundMethodIncretins, diabetes, and bariatric surgery: a review
Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 57
Incretin-based therapies: where will we be 50 years from now?
Meier, J. J., & Nauck, M. A. (2015) · Diabetologia · doi:10.1007/s00125-015-3608-6 · Cited by 58
“Physiological experiments in human volunteers revealed different increments in insulin secretion after oral and intravenous glucose administration, which were subsequently attributed to the actions of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1].”
BackgroundSelf-citationGlucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function
Davis, E., & Sandoval, D. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190025 · Cited by 60
Vollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 51
“prandial hyperglycemia in such patients (14).”
Do we really know why diabetes remits after gastric bypass surgery?
Laferrère, B. (2011) · Endocrine · doi:10.1007/s12020-011-9514-x · Cited by 52
“The incretin effect on insulin secretion is impaired in patients with T2DM [ 17 ].”
Aaboe, K., Knop, F. K., Vilsboll, T., Vølund, A., Simonsen, U., Deacon, C. F., Madsbad, S., Holst, J. J., & Krarup, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1731 · Cited by 53
“tients with type 2 diabetes (1) has become a key target in the treat-”
BackgroundSolomon, T. P. J., Knudsen, S. H., Karstoft, K., Winding, K., Holst, J. J., & Pedersen, B. K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2097 · Cited by 51
Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.
Jackson, S., Martin, T. S., Jones, J. D., Seal, D., & Emanuel, F. S. (2010) · PubMed · Cited by 74
Mentlein, R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.1.57 · Cited by 58
“It has been shown that the incretin effect is greatly impaired in Type 2 diabetes [9], and that continuous intravenous infusion of GLP-1 normalises plasma glucose concentrations in Type 2 diabetic patients without inducing hypoglycaemia [10].”
BackgroundGIP analogues and the treatment of obesity-diabetes
Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 59
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
“It is now thought that healthy individuals may derive up to 70% of their prandial insulin secretory response from the incretin effect.(24) Under normal conditions, the incretin peptides are secreted as needed, in response to ingested nutrients, and have a short plasma half-life due to degradation by the ubiquitous DPP…”
BackgroundIncretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Knop, F. K., Hansen, K. B., & Knop, F. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7004 · Cited by 64
“28,29 This pathophysiological trait is likely to play a central role in the inability of these patients to secrete sufficient amount of insulin to prevent hyperglycemia following oral glucose.”
Incretin Hormone Secretion Over the Day
Åhrén, B., Carr, R. D., & Deacon, C. F. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00007-2 · Cited by 54
The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
Rotenstein, L. S., Kozak, B. M., Shivers, J. P., Yarchoan, M. M., Close, J., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.2.44 · Cited by 56
Ileal Interposition with Sleeve Gastrectomy for Control of Type 2 Diabetes
Kumar, K. V. S. H., Ugale, S. M., Gupta, N., Naik, V., Kumar, P., Bhaskar, P., & Modi, K. D. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0070 · Cited by 51
“13 Glucagon-like peptide hormone also influences glucose metabolism by inhibiting glucagon secretion, delaying gastric emptying, and stimulating glycogenesis.”
The incretin hormones: from scientific discovery to practical therapeutics
Mudaliar, S. R. D., & Henry, R. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2561-x · Cited by 50
Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies
Meece, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167336 · Cited by 50
Belinova, L., Kahleova, H., Malinska, H., Topolcan, O., Vrzalova, J., Oliyarnyk, O., Kazdova, L., Hill, M., & Pelikanova, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107561 · Cited by 48
The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
Pi-Sunyer, F. X. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1785 · Cited by 49
Pathophysiology of type 2 diabetes: targeting islet cell dysfunction.
Spellman, C. (2010) · PubMed · Cited by 61
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T. E., Tovar-y-Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48
Coulter‐Parkhill, A., McClean, S., Gault, V. A., & Irwin, N. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211006071 · Cited by 55
Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism
Pannain, S., & Mokhlesi, B. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.07.007 · Cited by 54
Retlich, S., Duval, V., Graefe‐Mody, U., Jaehde, U., & Staab, A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009356444 · Cited by 50
“Decreased incretin levels have in fact been reported for diabetic patients.(15) DPP-4 inhibitors have been shown to alleviate this deficiency and reduced glucose and HbA1c successfully.”
BackgroundEJE PRIZE 2018: A gut feeling about glucagon
Knop, F. K. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0197 · Cited by 47
Gastrointestinal morbidity in obesity
Acosta, A. J., & Camilleri, M. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12385 · Cited by 53
Nguyen, K. T., & Körner, J. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0481-5 · Cited by 51
Hui, S., Huang, L., Wang, X., Zhu, X., Zhou, M., Chen, M., Yi, L., & Mi, M. (2020) · The FASEB Journal · doi:10.1096/fj.201902618rr · Cited by 52
Nauck, M. A., B�sing, M., �rskov, C., Siegel, E. G., Talartschik, J., Baartz, A., Baartz, T., Hopt, U. T., Becker, H. D., & Creutzfeldt, W. (1993) · Acta Diabetologica · doi:10.1007/bf00572873 · Cited by 50
“after oral glucose stimulation [24], but it is not known”
BackgroundMethodInfluentialSelf-citationThe cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
“There is evidence to suggest that the incretin system is functionally impaired in people with T2D, although this is not universally observed [27-31].”
BackgroundAnti‐inflammatory effects of linagliptin in hemodialysis patients with diabetes
Nakamura, Y., Tsuji, M., Hasegawa, H., Kimura, K., Fujita, K., Inoue, M., Shimizu, T., Gotoh, H., Goto, Y., Inagaki, M., et al. (2014) · Hemodialysis International · doi:10.1111/hdi.12127 · Cited by 46
Gastro-intestinal hormones GIP and GLP-1
Kieffer, T. J. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95625-9 · Cited by 49
“15 orally versus intravenously [66] (fig.”
Svendsen, P. F., Jensen, F. K., Holst, J. J., Haugaard, S. B., Nilas, L., & Madsbad, S. (2012) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2012.691542 · Cited by 47
Nauck, M. A., Walberg, J., Vethacke, A., El-Ouaghlidi, A., Senkal, M., Holst, J. J., Gallwitz, J. B., Schmidt, W. E., & Schmiegel, W. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.11.003 · Cited by 47
Self-citationNutrient Regulation of the Enteroinsular Axis And Insulin Secretion
Morgan, L. M., Flatt, P. R., & Marks, V. (1988) · Nutrition Research Reviews · doi:10.1079/nrr19880008 · Cited by 46
Dervisevic, M., Esser, L., Chen, Y., Alba, M., Prieto‐Simón, B., & Voelcker, N. H. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116995 · Cited by 51
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.